A preclinical and clinical review of aflibercept for the management of cancer

Cancer Treatment Reviews

Volumn 38, Issue 5, 2012, Pages 484-493

  Gaya, Andrew ^a   Tse, Vivien ^a  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Aflibercept; Angiogenesis; Bevacizumab; Clinical trial; Review; Safety; Vascular endothelial growth factor; VEGF Trap; VEGFR

Indexed keywords

AFLIBERCEPT; AXITINIB; BEVACIZUMAB; BRIVANIB ALANINATE; CEDIRANIB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; LAPATINIB; LINIFANIB; MOTESANIB; NINTEDANIB; OXALIPLATIN; PACLITAXEL; PAZOPANIB; PEMETREXED; PI 88; PLACEBO; PREDNISONE; RAMUCIRUMAB; RITUXIMAB; SORAFENIB; TIVOZANIB; TRASTUZUMAB; TREBANANIB; UNINDEXED DRUG; VANDETANIB; VATALANIB;

ADVANCED CANCER; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ASTHENIA; B CELL LYMPHOMA; BILE DUCT CANCER; BLEEDING; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM DISEASE; CENTRAL NERVOUS SYSTEM ISCHEMIA; CLINICAL EFFECTIVENESS; COLORECTAL CANCER; DRUG DOSE ESCALATION; DRUG MECHANISM; DRUG SAFETY; DYSPHONIA; FATIGUE; GASTROINTESTINAL HEMORRHAGE; GLIOBLASTOMA; GLIOMA; HOARSENESS; HUMAN; HYPERTENSION; INFECTION; ISCHEMIA; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MALIGNANT ANAPLASTIC GLIOMA; MESOTHELIOMA; MYALGIA; NAUSEA AND VOMITING; NEOPLASM; NEUTROPENIA; OVARY CANCER; OVERALL SURVIVAL; PANCREAS CANCER; PROGRESSION FREE SURVIVAL; PROTEINURIA; REVIEW; SARCOMA; SOLID TUMOR; STOMACH CANCER; STOMATITIS; THROMBOSIS; TREATMENT INDICATION; TREATMENT RESPONSE;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG SCREENING ASSAYS, ANTITUMOR; FLUOROURACIL; HUMANS; LEUCOVORIN; LUNG NEOPLASMS; RECOMBINANT FUSION PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84861190138     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2011.12.008     Document Type: Review

References (121)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971, 285:1182-1186.
2. Folkman J., Klagsbrun M. Angiogenic factors. Science 1987, 235:442-447.
3. Zetter B.R. Angiogenesis and tumor metastasis. Ann Rev Med 1998, 49:407-424.
4. Tong R.T., Boucher Y., Kozin S.V., Winkler F., Hicklin D.J., Jain R.K. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 2004, 64:3731-3736.
5. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307:58-62.
6. Morikawa S., Baluk P., Kaidoh T., Haskell A., Jain R.K., McDonald D.M. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol 2002, 160:985-1000.
7. Casanovas O., Hicklin D.J., Bergers G., Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005, 8:299-309.
8. Lyden D., Hattori K., Dias S., et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 2001, 7:1194-1201.
9. Santarelli J.G., Udani V., Yung Y.C., et al. Incorporation of bone marrow-derived Flk-1-expressing CD34+ cells in the endothelium of tumor vessels in the mouse brain. Neurosurgery 2006, 59:374-382.
10. Holash J., Maisonpierre P.C., Compton D., et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999, 284:1994-1998.
11. Hida K., Hida Y., Amin D.N., et al. Tumor-associated endothelial cells with cytogenetic abnormalities. Cancer Res 2004, 64:8249-8255.
12. Seaman S., Stevens J., Yang M.Y., Logsdon D., Graff-Cherry C., St Croix B. Genes that distinguish physiological and pathological angiogenesis. Cancer Cell 2007, 11:539-554.
13. Ellis L.M., Hicklin D.J. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 2008, 8:579-591.
14. Lohela M., Bry M., Tammela T., Alitalo K. VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol 2009, 21:154-165.
15. Cao Y. Positive and negative modulation of angiogenesis by VEGFR1 ligands. Sci Signal 2009, 2:re1.
16. André T., Kotelevets L., Vaillant J.C., et al. Vegf, Vegf-B, Vegf-C and their receptors KDR, FLT-1 and FLT-4 during the neoplastic progression of human colonic mucosa. Int J Cancer 2000, 86:174-181.
17. Donnini S., Machein M.R., Plate K.H., Weich H.A. Expression and localization of placenta growth factor and PlGF receptors in human meningiomas. J Pathol 1999, 189:66-71.
18. Fischer C., Mazzone M., Jonckx B., Carmeliet P. FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?. Nat Rev Cancer 2008, 8:942-956.
19. Zhang F., Tang Z., Hou X., et al. VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis. Proc Natl Acad Sci USA 2009, 106:6152-6157.
20. Jussila L., Alitalo K. Vascular growth factors and lymphangiogenesis. Physiol Rev 2002, 82:673-700.
21. Lieu CH, Tran HT, Jiang Z, et al. The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer. J Clin Oncol 2011;29: 15(Suppl.):3533.
22. Khaliq A., Li X.F., Shams M., et al. Localisation of placenta growth factor (PIGF) in human term placenta. Growth Factors 1996, 13:243-250.
23. Vuorela P., Hatva E., Lymboussaki A., et al. Expression of vascular endothelial growth factor and placenta growth factor in human placenta. Biol Reprod 1997, 56:489-494.
24. Park J.E., Chen H.H., Winer J., Houck K.A., Ferrara N. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J Biol Chem 1994, 269:25646-25654.
25. Roy H., Bhardwaj S., Babu M., et al. Adenovirus-mediated gene transfer of placental growth factor to perivascular tissue induces angiogenesis via upregulation of the expression of endogenous vascular endothelial growth factor-A. Hum Gene Ther 2005, 16:1422-1428.
26. Carmeliet P., Moons L., Luttun A., et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 2001, 7:575-583.
27. Coxon A., Bready J., Min H., et al. Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody. Mol Cancer Ther 2010, 9:2641-2651.
28. Tse V., Xu L., Yung Y.C., Santarelli J.G., et al. The temporal-spatial expression of VEGF, angiopoietins-1 and 2, and Tie-2 during tumor angiogenesis and their functional correlation with tumor neovascular architecture. Neurol Res 2003, 25:729-738.
29. Meunier-Carpentier S., Dales J.P., Djemli A., et al. Comparison of the prognosis indication of VEGFR-1 and VEGFR-2 and Tie2 receptor expression in breast carcinoma. Int J Oncol 2005, 26:977-984.
30. Nakayama T., Hatachi G., Wen C.Y., et al. Expression and significance of Tie-1 and Tie-2 receptors, and angiopoietins-1, 2 and 4 in colorectal adenocarcinoma: Immunohistochemical analysis and correlation with clinicopathological factors. World J Gastroenterol 2005, 11:964-969.
31. Herbst R.S., Hong D., Chap L., et al. Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J Clin Oncol 2009, 27:3557-3565.
32. Mita A.C., Takimoto C.H., Mita M., et al. Phase 1 study of AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid tumors. Clin Cancer Res 2010, 16:3044-3056.
33. Avastin [package insert]. South San Francisco, CA: Genentech, Inc.; 2011.
34. Sutent [package insert]. New York, NY: Pfizer Inc.; 2010.
35. Nexavar [package insert]. Wayne, NJ: Bayer AG; 2011.
36. Votrient [package insert]. Research Triangle Park, NC: GlaxoSmithKline plc; 2010.
37. Ellis L.M., Hicklin D.J. Pathways mediating resistance to vascular endothelial growth factor-targeted therapy. Clin Cancer Res 2008, 14:6371-6375.
38. Bergers G., Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008, 8:592-603.
39. Zhu X., Wu S., Dahut W.L., Parikh C.R. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 2007, 49:186-193.
40. Ivy S.P., Wick J.Y., Kaufman B.M. An overview of small-molecule inhibitors of VEGFR signaling. Nat Rev Clin Oncol 2009, 6:569-579.
41. Holash J., Davis S., Papadopoulos N., et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 2002, 99:11393-11398.
42. Tew W.P., Gordon M., Murren J., et al. Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors. Clin Cancer Res 2010, 16:358-366.
43. Grothey A., Galanis E. Targeting angiogenesis: progress with anti-VegF treatment with large molecules. Nat Rev Clin Oncol 2009, 6:507-518.
44. Rudge J.S., Holash J., Hylton D., et al. VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade. Proc Natl Acad Sci USA 2007, 104:18363-18370.
45. Rudge J.S., Thurston G., Davis S., et al. VEGF trap as a novel antiangiogenic treatment currently in clinical trials for cancer and eye diseases, and VelociGene- based discovery of the next generation of angiogenesis targets. Cold Spring Harb Symp Quant Biol 2005, 70:411-418.
46. Willett C.G., Duda D.G., di Tomaso E., et al. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol 2009, 27:3020-3026.
47. Rini B.I., Michaelson M.D., Rosenberg J.E., et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 2008, 26:3743-3748.
48. Baffert F., Le T., Sennino B., et al. Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling. Am J Physiol Heart Circ Physiol 2006, 290:H547-H559.
49. Williams J.L., Cartland D., Rudge J.S., Egginton S. VEGF trap abolishes shear stress- and overload-dependent angiogenesis in skeletal muscle. Microcirculation 2006, 13:499-509.
50. Taylor P.D., Wilson H., Hillier S.G., Wiegand S.J., Fraser H.M. Effects of inhibition of vascular endothelial growth factor at time of selection on follicular angiogenesis, expansion, development and atresia in the marmoset. Mol Hum Reprod 2007, 13:729-736.
51. Fraser H.M., Wilson H., Silvestri A., Morris K.D., Wiegand S.J. The role of vascular endothelial growth factor and estradiol in the regulation of endometrial angiogenesis and cell proliferation in the marmoset. Endocrinology 2008, 149:4413-4420.
52. Fan X., Krieg S., Kuo C.J., et al. VEGF blockade inhibits angiogenesis and reepithelialization of endometrium. FASEB J 2008, 22:3571-3580.
53. Kim E.S., Serur A., Huang J., et al. Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. Proc Natl Acad Sci USA 2002, 99:11399-11404.
54. Huang J., Frischer J.S., Serur A., et al. Regression of established tumors and metastases by potent vascular endothelial growth factor blockade. Proc Natl Acad Sci USA 2003, 100:7785-7790.
55. Byrne A.T., Ross L., Holash J., et al. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin Cancer Res 2003, 9:5721-5728.
56. Fukasawa M., Korc M. Vascular endothelial growth factor-trap suppresses tumorigenicity of multiple pancreatic cancer cell lines. Clin Cancer Res 2004, 10:3327-3332.
57. Verheul H.M., Hammers H., van Erp K., et al. Vascular endothelial growth factor trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotopic murine renal cell cancer model. Clin Cancer Res 2007, 13:4201-4208.
58. Hoff BA, Bhojani MS, Rehemtulla A, Ross BD, Galban CJ. Multi-parametric imaging of tumor treatment response to VEGF blockade. In: Proceedings from the international society for magnetic resonance in medicine and European society for magnetic resonance in medicine joint annual meeting. May 1-7, 2010; Stockholm, Sweden. Abstract 2716.
59. Gomez-Manzano C., Holash J., Fueyo J., et al. VEGF Trap induces antiglioma effect at different stages of disease. Neuro Oncol 2008, 10:940-945.
60. Inai T., Mancuso M., Hashizume H., et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 2004, 165:35-52.
61. Adler A, Li B, Xia A, Burakov D, Papadopoulos N, Thurston G. Rapid effects of VEGF Trap on angiogenesis and tumor cell proliferation. In: Proceedings from the 98th American association for cancer research annual meeting. April 14-18, 2007; Los Angeles, CA. Abstract 2127.
62. Adler A, Eichten A, Kao C, Wei Y, Fury W, Lin C, et al. Identifying tumor vascular genes regulated by Aflibercept (VEGF Trap). In: Proceedings from the 99th American association for cancer research annual meeting. April 12-16, 2008; San Diego, CA. Abstract 2497.
63. Lassoued W., Murphy D., Tsai J., Oueslati R., Thurston G., Lee W.M. Effect of VEGF and VEGF Trap on vascular endothelial cell signaling in tumors. Cancer Biol Ther 2011, 10:1326-1333.
64. Le X.F., Mao W., Lu C., et al. Specific blockade of VEGF and HER2 pathways results in greater growth inhibition of breast cancer xenografts that overexpress HER2. Cell Cycle 2008, 7:3747-3758.
65. Hu L., Hofmann J., Holash J., Yancopoulos G.D., Sood A.K., Jaffe R.B. Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model. Clin Cancer Res 2005, 11(19 Pt. 1):6966-6971.
66. Lejeune P, Chiron M, Le Moigne R, Vrignaud P, Bissery M-C. Combination of the antiangiogenic agent aflibercept results in greater antitumor activity. In: Proceedings from the 99th American association for cancer research annual meeting. April 12-16, 2008; San Diego, CA. Abstract 1107.
67. Abrahams C, Li B, Parveen A, Thurston G. Combination of aflibercept (VEGF Trap) and docetaxel produces increased anti-tumor effects associated with enhanced changes to tumor vasculature. In: Proceedings from the 101st American association for cancer research annual meeting. April 17-21, 2010; Washington, DC. Abstract 5427.
68. Wachsberger P.R., Burd R., Cardi C., et al. VEGF trap in combination with radiotherapy improves tumor control in u87 glioblastoma. Int J Radiat Oncol Biol Phys 2007, 67:1526-1537.
69. Chiron M, Vrignaud P, Lejeune P, Demers B, Leopold D, Bissery MC. Synergistic activity of aflibercept (VEGF Trap) in combination with 5-fluorouracil and irinotecan in preclinical tumor models. In: Proceedings from the AACR-NCI-EORTC: molecular targets and cancer therapeutics. October 22-26, 2007; San Francisco, CA. Abstract A13.
70. Jin K., Shen Y., He K., Xu Z., Li G., Teng L. Aflibercept (VEGF Trap): one more double-edged sword of anti-VEGF therapy for cancer?. Clin Transl Oncol 2010, 12:526-532.
71. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335-2342.
72. Sandler A., Gray R., Perry M.C. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355:2542-2550. Erratum in: N Engl J Med 2007;356:318.
73. Miller K., Wang M., Gralow J., et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007, 357:2666-2676.
74. Escudier B., Eisen T., Stadler W.M. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356:125-134. Erratum in: N Engl J Med 2007;357:203.
75. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007, 356:115-124.
76. Kabbinavar F., Hurwitz H.I., Fehrenbacher L., et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003, 2:60-65.
77. Lockhart A.C., Rothenberg M.L., Dupont J., et al. Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. J Clin Oncol 2010, 28:207-214.
78. Dixon J.A., Oliver S.C.N., Olson J.L., Mandava N. VEGF Trap-Eye for the treatment of neovascular age-related macular degeneration. Expert Opin Investig Drugs 2009, 18:1573-1580.
79. Park JR, Hawkins DS, Ingle M, et al. A pediatric phase I trial and pharmacokinetic study of aflibercept (VEGF Trap): A Children's Oncology Group Phase I Consortium study. J Clin Oncol 2010;28(15s) [abstract 9530].
80. Fricke I., Mirza N., Dupont J., et al. Vascular endothelial growth factor-trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses. Clin Cancer Res 2007, 13:4840-4848.
81. de Groot J.F., Lamborn K.R., Chang S.M., et al. Phase II study of aflibercept in recurrent malignant glioma: a North American brain tumor consortium study. J Clin Oncol 2011, 29:2689-2695.
82. Colombo N, Mangili G, Mammoliti S, et al. Aflibercept (VEGF Trap) for advanced epithelial ovarian cancer (EOC) patients (pts) with symptomatic malignant ascites: preliminary results of a pilot study. J Clin Oncol 2008;26(15s) [abstract 14598].
83. Vergote I, Amant F, Advani S, et al. Intravenous aflibercept in advanced ovarian cancer patients with recurrent symptomatic malignant ascites: key efficacy and safety results of a phase II, randomized, double-blind, placebo-controlled study. In: Proceedings from the 16th international meeting of the European society for of gynecological oncology (ESGO). October 11-14, 2009; Belgrade, Serbia.
84. Leighl N.B., Raez L.E., Besse B., et al. A multicenter, phase 2 study of vascular endothelial growth factor trap (Aflibercept) in platinum- and erlotinib-resistant adenocarcinoma of the lung. J Thorac Oncol 2010, 5:1054-1059.
85. Twardowski P., Stadler W.M., Frankel P., et al. Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial. Urology 2010, 76:923-926.
86. de Groot J.F., Piao Y., Tran H.T., et al. Myeloid biomarkers associated with glioblastoma response to anti-VEGF therapy with aflibercept. Clin Cancer Res 2011, 17:4872-4881.
87. Sanofi-Aventis; Regeneron Pharmaceuticals. Study of AVE0005 (VEGF Trap) in patients With chemoresistant advanced ovarian cancer. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2011 October 7]. Available from: NLM Identifier: ctgov:NCT00327171.
88. Tew WP, Colombo N, Ray-Coquard I, et al. VEGF-Trap for patients (pts) with recurrent platinum- resistant epithelial ovarian cancer (EOC): Preliminary results of a randomized, multicenter phase II study [ASCO abstract 5508]. J Clin Oncol 2007;25(18s).
89. Runyon B.A. Paracentesis of ascitic fluid. A safe procedure. Arch Intern Med 1986, 146:2259-2261.
90. Luo J.C., Toyoda M., Shibuya M. Differential inhibition of fluid accumulation and tumor growth in two mouse ascites tumors by an antivascular endothelial growth factor/permeability factor neutralizing antibody. Cancer Res 1998, 58:2594-2600.
91. Numnum T.M., Rocconi R.P., Whitworth J., Barnes M.N. The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma. Gynecol Oncol 2006, 102:425-428.
92. Hamilton C.A., Maxwell G.L., Chernofsky M.R., Bernstein S.A., Farley J.H., Rose G.S. Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer. Gynecol Oncol 2008, 111:530-532.
93. Kesterson J.P., Mhawech-Fauceglia P., Lele S. The use of bevacizumab in refractory ovarian granulosa-cell carcinoma with symptomatic relief of ascites: a case report. Gynecol Oncol 2008, 111:527-529.
94. Hu L., Hofmann J., Holash J., Yancopoulos G.D., Sood A.K., Jaffe R. Vascular endothelial growth factor Trap combined with paclitaxel stilingly inhibits tumor and ascites, prolongs survival in a human ovarian cancer model. Clin Cancer Res 2005, 11:6966-6971.
95. Sanofi-Aventis; Regeneron Pharmaceuticals, National Surgical Adjuvant Breast and Bowel Project (NSABP). Aflibercept versus placebo in combination with irinotecan and 5-FU in the treatment of patients with metastatic colorectal cancer after failure of an oxaliplatin based regimen (VELOUR). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2011 October 7]. Available from: NLM Identifier: ctgov:NCT00561470.
96. Van Cutsem E, Tabernero J, Lakomy R, et al. Intravenous Aflibercept versus placebo in combination with irinotecan/5-FU (FOLFIRI) for second-line treatment of metastatic colorectal cancer (mCRC): results of a multinational Phase III trial (EFC10262-VELOUR). Ann Oncol 2011;22(s5) [abstract O-0024].
97. Sanofi-Aventis; Regeneron Pharmaceuticals. A study of aflibercept versus placebo in patients with second-line docetaxel for locally advanced or metastatic non-small-cell lung cancer (VITAL). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2011 October 7]. Available from: NLM Identifier: ctgov:NCT00532155.
98. Novello S, Ramlay R, Gorbunova VA, et al. Aflibercept in combination with docetaxel for second-line treatment of locally advanced or metastatic non-small-cell lung cancer (NSCLC): Final results of a multinational placebo-controlled phase III trial (EFC10261-VITAL). In: Proceedings from the international association for the study of lung cancer. July 3-7, 2011; Amsterdam, The Netherlands. Abstract O43.06.
99. Riess H, Manges R, Karasek P, et al. Double-blind, placebo-controlled randomized phase III trial of aflibercept (A) plus gemcitabine (G) versus placebo (P) plus gemcitabine (G) in patients with metastatic pancreatic cancer: Final results. In: Proceedings from the 12th world congress on gastrointestinal cancer. June 30-July 3, 2010; Barcelona, Spain. Abstract O-0006.
100. Sanofi-Aventis. Study of aflibercept and modified FOLFOX6 as first-line treatment in patients with metastatic colorectal cancer (AFFIRM). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2011 October 7]. Available from: NLM Identifier: ctgov:NCT00851084.
101. Sanofi-Aventis; Regeneron Pharmaceuticals. Aflibercept in combination with docetaxel in metastatic androgen independent prostate cancer (VENICE). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2011 October 7]. Available from: NLM Identifier: ctgov:NCT00519285.
102. Kuhnowski F, Thieblemont C, Jardin F, et al. A phase I study of IV aflibercept (Afl) in combination with R-CHOP in untreated patients (pts) with B-cell lymphoma. J Clin Oncol 2010;28(15s) [abstract 8010].
103. Freyer G., Fumoleau P., You B., Isambert N., Chevalier P., Trillet-Lenoir V. A phase I dose escalation and pharmacokinetic (PK) study of intravenous (iv) aflibercept (VEGF Trap) plus docetaxel (D) and cisplatin (C) in patients (pts) with advanced solid tumors: preliminary results. J Clin Oncol 2008, 26(15s). [abstract 14539].
104. Limentani SA, Just R, Purdham A, et al. A phase I dose escalation and pharmacokinetic (PK) study of intravenous (iv) aflibercept (VEGF Trap) plus FOLFOX4 in patients (pts) with advanced solid tumors: preliminary results. J Clin Oncol 2008;26(15s) [abstract 3556].
105. Patnaik A, Pipas M, Rosen L, et al. A phase I dose escalation and pharmacokinetic (PK) study of intravenous (iv) aflibercept (VEGF Trap) plus weekly gemcitabine (Gem) in patients (pts) with advanced solid tumors: preliminary results. J Clin Oncol 2008;26(15s) [abstract 3558].
106. Rixe O, Verslype C, Khayat C, et al. A phase I dose escalation (DE) and pharmacokinetics (PK) study of intravenous aflibercept (VEGF Trap) plus irinotecan, 5-fluorouracil, and leucovorin (I-LV5FU2) in patients with advanced solid tumors (STs). J Clin Oncol 2008;26(15s) [abstract 3557].
107. Isambert N, Freyer G, Zanetta S, et al. A phase I dose escalation and pharmacokinetic (PK) study of intravenous aflibercept (VEGF trap) plus docetaxel (D) in patients (pts) with advanced solid tumors: preliminary results. J Clin Oncol 2008;26(May 20 Suppl.) [abstract 3599].
108. Verslype C, Spano J, Van Cutsem E, et al. Validation of the selected dose of aflibercept (VEGF Trap) plus irinotecan, 5-fluorouracil, and leucovorin (I-LV5FU2) in a phase I clinical trial of patients (pts) with advanced solid tumors (STs): preliminary results. J Clin Oncol 2008;26(15s) [abstract 14540].
109. Townsley C.A., Siu L.L., San Pedro-Salcedo M., Liu L., Wakelee H.A. A phase I study of aflibercept, pemetrexed (P), and cisplatin (C) in patients with advanced solid tumors. J Clin Oncol 2010, 28(15s). [abstract 2536].
110. Coleman RL, Duska LR, Ramirez PT, et al. Phase II multi-institutional study of docetaxel plus aflibercept (AVE0005, NSC# 724770) in patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer. J Clin Oncol 2011;29(Suppl.) [abstract 5017].
111. Sherman EJ, Ho AL, Haque S, et al. A phase II study of VEGF trap (aflibercept) in patients with radioactive iodine-refractory, positron emission tomography (PET) positive thyroid carcinoma. J Clin Oncol 2010;28(15s) [abstract 5587].
112. Tang P., Cohen S.J., Bjarnason G.A., Kollmannsberger C., Virik K., MacKenzie M.J., et al. Phase II trial of aflibercept (VEGF Trap) in previously treated patients with metastatic colorectal cancer (MCRC): a PMH phase II consortium trial. J Clin Oncol 2008, 26(15s). [abstract 4027].
113. Massarelli E, Miller VA, Leighl N, et al. Phase II study of the efficacy and safety of intravenous (IV) AVE0005 (VEGF Trap) given every 2 weeks in patients (Pts) with platinum- and erlotinib-resistant adenocarcinoma of the lung (NSCLA). J Clin Oncol 2007;25(18s) [abstract 7627].
114. Tarhini AA, Christensen S, Frankel P, et al. Phase II study of aflibercept (VEGF trap) in recurrent inoperable stage III or stage IV melanoma of cutaneous or ocular origin. J Clin Oncol 2009;27(15s) [abstract 9028].
115. Townsley C., Hirte H., Hoskins P., Buckanovich R., Mackay H., Welch S., et al. A phase II study of aflibercept (VEGF trap) in recurrent or metastatic gynecologic soft-tissue sarcomas: A study of the Princess Margaret Hospital Phase II Consortium. J Clin Oncol 2009, 27(15s). [abstract 5591].
116. Eastern Cooperative Oncology Group; National Cancer Institute (NCI). VEGF Trap in treating patients with metastatic or unresectable kidney cancer. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2011 October 7]. Available from: NLM Identifier: ctgov:NCT00357760.
117. Gynecologic Oncology Group; National Cancer Institute (NCI). VEGF Trap in treating patients with recurrent or persistent endometrial cancer. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2011 October 7]. Available from: NLM Identifier: ctgov:NCT00462826.
118. Weill Medical College of Cornell University; National Cancer Institute (NCI). VEGF Trap in treating patients with stage II or stage III multiple myeloma that has relapsed or not responded to previous treatment. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2011 October 7]. Available from: NLM Identifier: ctgov:NCT00437034.
119. California Cancer Consortium; National Cancer Institute (NCI), Aflibercept in treating patients with myelodysplastic syndromes. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2011 October 7]. Available from: NLM Identifier: ctgov:NCT00509249.
120. Teng L.-S., Jin D.-T., He K.-F., Zhang J., Wang H-H C.J. Clinical applications of VEGF-Trap (aflibercept) in cancer treatment. J Chin Med Assoc 2010, 73:449-456.
121. Wulff C., Wilson H., Wiegand S.J., Rudge J.S., Fraser H.M. Prevention of thecal angiogenesis, antral follicular growth, and ovulation in the primate by treatment with vascular endothelial growth factor Trap R1R2. Endocrinology 2002, 143:2797-2807.